| 2014-11-19 |
咪唑-4-酮及咪唑-4-硫酮化合物 |
ZL200910006503.9/2014-11-19 |
|
| 2014-11 |
Discovery of multiple kinases inhibitors, DBPR114, as the novel anti-cancer agent |
European Journal of Cancer. 2014 Nov;50(Suppl. 6):92-93. |
 |
| 2014-10 |
Novel irreversible EGFR tyrosine kinase inhibitor, DBPR112, as a therapeutic candidate for lung adenocarcinoma |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 1756. |
|
| 2014-08-15 |
Anticancer oral formulation |
特許第5596680號/2014-08-15 |
|
| 2014-06-04 |
抗癌口服制剂 |
ZL200980126979.4/2014-06-04 |
|
| 2014-05 |
Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells |
Journal of Medicinal Chemistry. 2014 May;57(10):4009-4022. |
|
| 2014-04-21 |
咪唑-4-酮及咪唑-4-硫酮化合物 |
I434686/2014-04-21 |
|
| 2014-04 |
Antimitotic and vascular disrupting agents: 2-hydroxy-3,4,5-trimethoxybenzophenones |
European Journal of Medicinal Chemistry. 2014 Apr 22;77(2):306-314. |
|
| 2014-03 |
DBPR112, a potent and selective EGFR kinase inhibitor in preclinical study |
Abstracts of Papers - American Chemical Society. 2014 Mar;247:Article number 315-MEDI. |
|
| 2014-01-08 |
Evaluation of the antitumor effects of BPR1J-340, a potent and selective FLT3 inhibitor, alone or in combination with an HDAC inhibitor, vorinostat, in AML cancer |
PLoS ONE. 2014 Jan 8;9(1):Article number e83160. |
|
| 2013-11-13 |
Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5 -(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a novel peripherally restricted cannabinoid-1 receptor antagonist with significant weight-loss efficacy in diet-induced obese mice |
Journal of Medicinal Chemistry. 2013 Nov 13;56(24):9920-9933. |
|
| 2013-11 |
BPR0C305, an orally active microtubule-disrupting anticancer agent |
Anticancer Drugs. 2013 Nov;24(10):1047-1057. |
|
| 2013-11 |
A development drug candidate targeting EGFR kinase for lung cancer: DBPR112 |
Journal of Thoracic Oncology. 2013 Nov;8(Suppl. 2):S779-S780. |
|
| 2013-07-08 |
1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors |
ChemBioChem. 2013 Jul 8;14(10):1248-1254. |
|
| 2013-07-08 |
Inside Cover: 1-arylsulfonyl-5-(N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors(ChemBioChem 10/2013) |
ChemBioChem. 2013 Jul 8;14(10):1150. |
|
| 2013-07 |
CYP1A2 genetic polymorphisms are associated with early antidepressant escitalopram metabolism and adverse reactions |
Pharmacogenomics. 2013 Jul;14(10):1191-1201. |
|
| 2013-06-05 |
Anticancer oral formulation |
EP2310363B1/2013-06-05 |
|
| 2013-06 |
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3) |
Bioorganic and Medicinal Chemistry. 2013 Jun;21(11):2856-2867. |
|
| 2013-04-13 |
Exploration of the role of tylophorine E ring in anti-Coronavirus activity-Tylophorine derived dibenzoquinolines impart multi-biological activities as orally active agents |
FASEB Journal. 2013 Apr 13;27:lb71. |
|
| 2013-04-07 |
BPR000K, a novel Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 300-MEDI. |
|
| 2013-04-07 |
3D-QSAR assisted drug design: Identification of a potent quinazoline based Aurora kinase inhibitor |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 87-MEDI. |
|
| 2013-04-07 |
Development drug candidate targeting EGFR kinase: DBPR112 |
Abstracts of Papers - American Chemical Society. 2013 Apr 7;245:Article number 299-MEDI. |
|
| 2013-02-11 |
抗癌口服藥學組成物 |
I384984/2013-02-11 |
|
| 2013-02 |
Resistance studies of a di-thiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems |
Antimicrobial Agents and Chemotherapy. 2013 Feb; 57(2):723-733. |
|
| 2013-01-15 |
Imidazol-4-one and imidazole-4-thione compounds |
US8354442B2/2013-01-15 |
|
